There is no defensible rule that every stool test is more accurate than every other H. pylori test. Laboratory stool antigen testing and urea breath testing are established non-invasive options. Molecular stool tests form a separate category, and their performance must be assessed assay by assay. Current diagnostic review
The best starting question is what you need to find out: whether infection is present, whether treatment worked, whether resistance information would help, or whether symptoms need a broader medical assessment.
The comparison at a glance
| Method | What it looks for | Where it can help | What to keep in mind |
|---|---|---|---|
| Laboratory stool antigen | H. pylori proteins | Initial testing and checking eradication | Preparation and the specific laboratory assay matter |
| Urea breath test | Evidence of bacterial urease activity | Initial testing and checking eradication | Requires the test substance and timed breath collection |
| Stool PCR or another molecular assay | Targeted DNA; sometimes resistance variants | Selected diagnostic and resistance questions | Validation and intended use are assay-specific |
| GI-MAP H. pylori component | DNA quantity and selected genetic markers | A particular molecular report for clinical interpretation | It does not inherit validation from other PCR assays |
| Blood antibody | Antibodies made after exposure | Selected situations assessed by a clinician | Cannot reliably distinguish past from current infection; unsuitable for confirming cure |
| Endoscopy with biopsy-based testing | Tissue changes, organisms or their activity; sometimes culture or molecular targets | When direct examination or specialist investigation is indicated | Invasive; the sampling and laboratory method affect results |
The categories and clinical roles above are described by Mayo Clinic, MedlinePlus and the 2026 diagnostic review. GI-MAP specifications come from the manufacturer.
If your clinician has narrowed the choice to two conventional methods, our stool antigen versus breath test guide compares the practical arrangements.
Is a stool test the most accurate option?
“Stool test” describes the specimen, not one technology. A stool antigen immunoassay, a PCR assay and a broad microbiome panel are different products. Evidence about one cannot prove the accuracy of another.
A Cochrane review found that indirect comparisons favored urea breath testing over stool antigen and blood tests, while the few direct comparisons were uncertain. Most included studies had substantial methodological limitations, and its searches ended in 2016. It cannot establish a permanent ranking of today's products—and it does not validate GI-MAP. Cochrane review
For a percentage to mean anything, ask: Which assay? In which patients? Compared with which reference test? Before or after treatment? Were interfering medicines excluded?
Sensitivity concerns finding infection when it is present. Specificity concerns correctly identifying people without it. Neither number, on its own, tells you the probability that your particular result is correct. A sales comparison that lists percentages from unrelated studies can look precise while answering the wrong question.
Does detecting less DNA mean better diagnosis?
Not necessarily. Analytical sensitivity describes detection under specified laboratory conditions. Clinical performance asks how the test behaves in actual patients. A test must also avoid misleading positives, produce interpretable results and help answer the medical question.
For example, Mayo researchers studied their own stool PCR assay against stool antigen testing. Those results concern that assay, specimen set and comparator. They cannot be presented as GI-MAP accuracy figures. Marrero Rolon et al., 2021
What independent evidence exists about GI-MAP?
A small 2020 laboratory study raised concerns about inconsistent GI-MAP pathogen results, including unexpected H. pylori detections. It used prepared aliquots from one healthy donor, not a representative clinical patient population. It was funded by Doctor's Data, another laboratory, and could not resolve H. pylori discrepancies with a reference PCR assay. It is a reason to ask for better validation, not a basis for assigning today's GI-MAP H. pylori test a clinical accuracy percentage. Gingras and Maggiore
The manufacturer describes internal validation. That is relevant product information, but it is different from an independent, current clinical comparison. The evidence reviewed here does not justify calling GI-MAP the most accurate H. pylori test.
Is home collection useful?
It can be. Stool collection can take place privately at home, avoiding a breath-sample appointment. However, “at home” may mean collecting a sample and sending it to a laboratory, rather than reading an immediate result yourself. Check the test method, transport instructions and who will explain the result.
Convenience is a legitimate reason to discuss an option. It does not make accuracy or clinical suitability automatic. A kit that cannot reach the lab within its acceptance window may not be convenient for your circumstances.
What about cost and a larger panel?
Compare the full pathway: the first test, any required appointment, interpretation, treatment if appropriate and follow-up testing. Ask your insurer about the exact service before relying on reimbursement. Prices for unlike tests do not establish which offers better medical value.
Our US testing-cost guide includes dated price examples and a checklist for obtaining a complete quote.
On this site, the focused H. pylori Profile is separate from the broader GI-MAP panels, which already include H. pylori. If the only question is whether you have this infection, ask whether a standard stool antigen or breath test would answer it. If you and your clinician are considering molecular testing, ask which resistance or reporting information would change the care plan.
Before choosing: bring that question to your clinician, and use our sample report to see what the branded panel actually reports. Our central H. pylori guide explains when medical assessment should come first.
Sources: Mayo Clinic; MedlinePlus; Tang et al. 2026; Cochrane 2018; Marrero Rolon et al. 2021 with 2022 probe-sequence erratum; Gingras and Maggiore 2020; DSL methodology guide. All are linked inline; manufacturer evidence is identified as such.
For a correction or source question, contact GI MAP Test.